Jakob Christiane, Liersch Torsten, Meyer Wolfdietrich, Baretton Gustavo B, Häusler Peter, Schwabe Wolfgang, Becker Heinz, Aust Daniela E
Institute for Pathology, University of Technology, Fetscherstrasse 74, D-01307 Dresden, Germany.
Am J Surg Pathol. 2005 Oct;29(10):1304-9. doi: 10.1097/01.pas.0000170346.55304.88.
In locally advanced rectal cancer, neoadjuvant 5-fluorouracil (5-FU)-based long-term chemoradiotherapy leads to marked tumor reduction and decrease of local recurrence rate. Thymidylate synthase (TS), thymidine phosphorylase (TP), and dihydropyrimidine dehydrogenase (DPD) are known to be important biomarkers to predict tumor response to 5-FU-based therapy. The aim of this study was to examine the correlation between TS, TP, and DPD protein expression and histopathologic tumor regression after neoadjuvant chemoradiotherapy. The results were compared with the recently published mRNA data. Preoperative biopsies (n = 25) and resection specimens (n = 40) from patients with rectal carcinoma (clinical UICC stage II/III) receiving neoadjuvant 5-FU-based chemoradiotherapy were studied for TS, TP, and DPD protein expression by immunohistochemistry using three different scoring systems (intensity, pattern, intensity + pattern). Results were compared with histopathologic tumor regression. A significant correlation between protein expression and tumor response was only seen when both staining intensity and staining pattern were considered. With this method, a significant association was seen between high TS expression in tumor biopsies as well as resection specimens and nonresponse of the tumor to therapy (P = 0.04). Furthermore, low TP expression in the resection specimens was significantly associated with lack of response (P = 0.02). For DPD no significant correlations were found at all. In conclusion, these results suggest that immunohistochemistry like RT-PCR is a suitable method to determine the correlation between TS, TP, and DPD expression and histopathologic tumor regression. However, precise results can only be achieved if staining intensity as well as staining pattern within the tumors are evaluated.
在局部晚期直肠癌中,基于新辅助5-氟尿嘧啶(5-FU)的长期放化疗可使肿瘤显著缩小,并降低局部复发率。已知胸苷酸合成酶(TS)、胸苷磷酸化酶(TP)和二氢嘧啶脱氢酶(DPD)是预测肿瘤对基于5-FU治疗反应的重要生物标志物。本研究的目的是探讨新辅助放化疗后TS、TP和DPD蛋白表达与组织病理学肿瘤消退之间的相关性。将结果与最近发表的mRNA数据进行比较。对接受新辅助基于5-FU放化疗的直肠癌患者(临床UICC分期II/III)的术前活检标本(n = 25)和切除标本(n = 40),采用三种不同的评分系统(强度、模式、强度 + 模式)通过免疫组织化学研究TS、TP和DPD蛋白表达。将结果与组织病理学肿瘤消退进行比较。仅当同时考虑染色强度和染色模式时,才观察到蛋白表达与肿瘤反应之间存在显著相关性。采用这种方法,在肿瘤活检标本以及切除标本中高TS表达与肿瘤对治疗无反应之间存在显著关联(P = 0.04)。此外,切除标本中低TP表达与无反应显著相关(P = 0.02)。对于DPD,根本未发现显著相关性。总之,这些结果表明,与逆转录聚合酶链反应(RT-PCR)一样,免疫组织化学是确定TS、TP和DPD表达与组织病理学肿瘤消退之间相关性的合适方法。然而,只有在评估肿瘤内的染色强度以及染色模式时才能获得精确结果。